HER2-POSITIVE BREAST CANCER MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-143963 |   Pharmaceuticals and Healthcare

Historical data: 2017 - 2023

Forecast period: 2025 - 2031

Quantitative units: Revenue in USD million and CAGR from 2025 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

HER2-Positive Breast Cancer Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL HER2-POSITIVE BREAST CANCER MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL HER2-POSITIVE BREAST CANCER MARKET

7.1 GLOBAL HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA HER2-POSITIVE BREAST CANCER MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 Pfizer (Pharmacia and Upjohn Company)

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Novartis

16.3 AstraZeneca Pharmaceuticals

16.4 Eli Lilly

16.5 Roche Group

16.6 Merck

16.7 Jiangsu HengRui Medicine

16.8 Odonate Therapeutics

16.9 Radius Pharmaceuticals

16.10 Immunomedics

16.11 Syndax Pharmaceuticals

16.12 Bayer

16.13 Eagle Pharmaceuticals

16.14 Merrimack Pharmaceuticals

16.15 GlaxoSmithKline

16.16 Millennium Pharmaceuticals

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type

Grifola Frondosa
Surgery
Radiation and Chemotherapy
Endocrine Therapy
Molecular Targeted Therapy

By Application

Hospital
Specialist Clinic
Biotechnology and Pharmaceutical Companies
Research and Academic Institutions

Companies

Pfizer (Pharmacia and Upjohn Company)
Novartis
AstraZeneca Pharmaceuticals
Eli Lilly
Roche Group
Merck
Jiangsu HengRui Medicine
Odonate Therapeutics
Radius Pharmaceuticals
Immunomedics
Syndax Pharmaceuticals
Bayer
Eagle Pharmaceuticals
Merrimack Pharmaceuticals
GlaxoSmithKline
Millennium Pharmaceuticals

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.